{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:40:08Z","timestamp":1756312808300,"version":"3.44.0"},"reference-count":10,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,4,24]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Dermatomyositis is a class of autoimmune connective tissue diseases characterised by skin rash and proximal myopathy. Research to date has shown a strong association between dermatomyositis and underlying malignancy. This report presents a case of rapidly progressing neuroendocrine carcinoma manifesting as paraneoplastic dermatomyositis in a relatively healthy middle-aged man. We aim to highlight the importance of having medical professionals be comfortable with identifying signs and symptoms of dermatomyositis in a timely and efficient manner. This report highlights the importance of being aware of the possibility of an underlying malignancy in a patient with dermatomyositis and being proficient in its workup<\/jats:p>","DOI":"10.1136\/bcr-2024-264148","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T03:10:19Z","timestamp":1746673819000},"page":"e264148","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["High-grade neuroendocrine carcinoma presenting as dermatomyositis"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5928-8705","authenticated-orcid":false,"given":"Sharon","family":"Santhosh","sequence":"first","affiliation":[{"name":"Internal Medicine, Northwell Health, New Hyde Park, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Musinsky","sequence":"additional","affiliation":[{"name":"Northwell Health, New Hyde Park, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Tracey","sequence":"additional","affiliation":[{"name":"Department of Radiology, Northwell Health, New Hyde Park, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Capustin","sequence":"additional","affiliation":[{"name":"Northwell Health, New Hyde Park, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"2025082709222722000_18.5.e264148.1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/acr.24786","article-title":"Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-Based Cohort Study","volume":"75","author":"Kronzer","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025082709222722000_18.5.e264148.2","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009639","article-title":"Evidence supports blind screening for internal malignancy in dermatomyositis","volume":"97","author":"Leatham","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2025082709222722000_18.5.e264148.3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.21037\/atm-20-5175","article-title":"Dermatomyositis autoantibodies: how can we maximize utility?","volume":"9","author":"Hodgkinson","year":"2021","journal-title":"Ann Transl Med"},{"key":"2025082709222722000_18.5.e264148.4","first-page":"409","article-title":"Dermatomyositis and malignancy","volume":"65","author":"Hu","year":"2019","journal-title":"Can Fam Physician"},{"key":"2025082709222722000_18.5.e264148.5","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2169\/internalmedicine.56.7768","article-title":"Dermatomyositis Associated with Lung Neuroendocrine Carcinoma","volume":"56","author":"Takashima","year":"2017","journal-title":"Intern Med"},{"key":"2025082709222722000_18.5.e264148.6","doi-asserted-by":"crossref","first-page":"432","DOI":"10.21037\/atm-20-5215","article-title":"Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?","volume":"9","author":"Khanna","year":"2021","journal-title":"Ann Transl Med"},{"doi-asserted-by":"publisher","key":"2025082709222722000_18.5.e264148.7","DOI":"10.1111\/j.1365-2133.2009.09274.x"},{"key":"2025082709222722000_18.5.e264148.8","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"The Lancet"},{"doi-asserted-by":"publisher","key":"2025082709222722000_18.5.e264148.9","DOI":"10.1016\/j.ejca.2011.08.012"},{"key":"2025082709222722000_18.5.e264148.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12894-020-00779-z","article-title":"Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation","volume":"21","author":"Minagawa","year":"2021","journal-title":"BMC Urol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-264148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:22:35Z","timestamp":1756311755000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-264148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":10,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,7]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bcr-2024-264148"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-264148","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}